These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38258129)

  • 21. Age-Appropriate Formulations Including Pharmaceutical Excipients in Neonatal Medicines.
    Kogermann K; Lass J; Nellis G; Metsvaht T; Lutsar I
    Curr Pharm Des; 2017; 23(38):5779-5789. PubMed ID: 28950820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric Safety of Polysorbates in Drug Formulations.
    Kriegel C; Festag M; Kishore RSK; Roethlisberger D; Schmitt G
    Children (Basel); 2019 Dec; 7(1):. PubMed ID: 31877624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates.
    Sridharan K; Hasan HM; Al Jufairi M; Al Daylami A; Al Ansari E; Qader AM; Pasha SAA
    Expert Opin Drug Saf; 2020 Dec; 19(12):1625-1640. PubMed ID: 32767900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics.
    Rayaprolu BM; Strawser JJ; Anyarambhatla G
    Drug Dev Ind Pharm; 2018 Oct; 44(10):1565-1571. PubMed ID: 29863908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive review on pharmaceutical excipients.
    Pockle RD; Masareddy RS; Patil AS; Patil PD
    Ther Deliv; 2023 Jul; 14(7):443-458. PubMed ID: 37464784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of Excipients in Pediatric Formulations-A Call for Toxicity Studies in Juvenile Animals?
    Schmitt G
    Children (Basel); 2015 May; 2(2):191-7. PubMed ID: 27417358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective and observational analysis of harmful excipients in medicines for hospitalised neonates in Latvia.
    Sviestina I; Mozgis D
    Eur J Hosp Pharm; 2018 Jul; 25(4):176-182. PubMed ID: 31157015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxic excipients in medications for neonates in Brazil.
    Souza A; Santos D; Fonseca S; Medeiros M; Batista L; Turner M; Coelho H
    Eur J Pediatr; 2014 Jul; 173(7):935-45. PubMed ID: 24500397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ensuring Product Stability - Choosing the Right Excipients.
    Veronica N; Heng PWS; Liew CV
    J Pharm Sci; 2022 Aug; 111(8):2158-2171. PubMed ID: 35526577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Overview of Pharmaceutical Excipients: Safe or Not Safe?
    Abrantes CG; Duarte D; Reis CP
    J Pharm Sci; 2016 Jul; 105(7):2019-26. PubMed ID: 27262205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.
    Walsh J; Cram A; Woertz K; Breitkreutz J; Winzenburg G; Turner R; Tuleu C;
    Adv Drug Deliv Rev; 2014 Jun; 73():14-33. PubMed ID: 24614069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medicines containing pharmaceutical excipients with known effects: a French review.
    Fusier I; Tollier C; Husson MC
    Pharm World Sci; 2003 Aug; 25(4):152-5. PubMed ID: 12964493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of presence of excipients in drug analysis in fed-state gastric biorelevant media.
    Baxevanis F; Kuiper J; Fotaki N
    Eur J Pharm Biopharm; 2018 Oct; 131():178-188. PubMed ID: 30110669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients.
    Binson G; Beuzit K; Migeot V; Marco L; Troussier B; Venisse N; Dupuis A
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 31003500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.
    Nellis G; Metsvaht T; Varendi H; Lass J; Duncan J; Nunn AJ; Turner MA; Lutsar I
    Paediatr Drugs; 2016 Jun; 18(3):221-30. PubMed ID: 27099961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovative, Sugar-Free Oral Hydrogel as a Co-administrative Vehicle for Pediatrics: a Strategy to Enhance Patient Compliance.
    Pereira M; Silva FC; Simões S; Ribeiro HM; Almeida AJ; Marto J
    AAPS PharmSciTech; 2022 Apr; 23(4):107. PubMed ID: 35381882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological Basis for Therapeutics. Pharmacological Analysis of Summary of Product Characteristics (SPC) for Physicians].
    Lechat P
    Therapie; 2015; 70(5):403-14. PubMed ID: 26109291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality and functionality of excipients.
    Pifferi G; Santoro P; Pedrani M
    Farmaco; 1999; 54(1-2):1-14. PubMed ID: 10321025
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.